Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Athersys Inc's Business Segments
Athersys Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
-
Regions Reported
-
Athersys Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Service100%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Service | $ 0 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Athersys Inc
Athersys Inc. is a biotechnology company that specializes in the development of novel stem cell therapies and regenerative medicine products. The company was founded in 1995 and is headquartered in Cleveland, Ohio.
Athersys focuses on developing proprietary platform technologies that enable the discovery, development, and commercialization of innovative treatments for various medical conditions. Their primary focus is on the use of adult stem cells, specifically MultiStem®, for the treatment of acute and chronic diseases.
MultiStem is a patented, off-the-shelf, stem cell product derived from adult bone marrow. It is designed to promote tissue repair and healing, reduce inflammation, and modulate immune responses. The therapeutic potential of MultiStem has been demonstrated in preclinical and clinical studies across multiple therapeutic areas, including ischemic stroke, acute respiratory distress syndrome (ARDS), trauma injuries, inflammatory bowel disease, and graft-versus-host disease (GVHD).
A key aspect of Athersys' strategy is forming strategic collaborations and partnerships with leading pharmaceutical and biotechnology companies. These collaborations allow them to leverage their platform technologies and expertise while accessing additional resources and capabilities to accelerate the development and commercialization of their products.
In terms of clinical development, Athersys has a robust pipeline of programs targeting various indications. Their lead program is focused on acute ischemic stroke, which is a significant unmet medical need with limited treatment options. Athersys has completed several clinical trials evaluating the use of MultiStem in ischemic stroke patients, including a Phase 2/3 trial in collaboration with Healios K.K. in Japan. Promising results from these trials have shown the potential of MultiStem to improve patient outcomes and reduce disability.
Aside from stroke, Athersys is also actively exploring the use of MultiStem in other areas such as ARDS, trauma, inflammatory bowel disease, and GVHD. The company is conducting clinical trials in these indications to assess the safety and efficacy of MultiStem in diverse patient populations.
In addition to its stem cell platform, Athersys is also exploring other technologies and product candidates. One example is their Optimized Neural Stem Cells (oNSCs) program, which aims to develop therapies for central nervous system (CNS) disorders such as spinal cord injury and multiple sclerosis.
Athersys has a strong research and development focus, with a team of dedicated scientists and clinicians working to advance their pipeline programs. They also have an experienced management team with a track record of success in the biopharmaceutical industry.
Overall, Athersys Inc. is a leading biotechnology company that is leveraging stem cell technology to develop innovative therapies for a range of medical conditions. With a pipeline of promising candidates and strategic partnerships in place, Athersys is positioned to make a significant impact in the field of regenerative medicine.
Athersys focuses on developing proprietary platform technologies that enable the discovery, development, and commercialization of innovative treatments for various medical conditions. Their primary focus is on the use of adult stem cells, specifically MultiStem®, for the treatment of acute and chronic diseases.
MultiStem is a patented, off-the-shelf, stem cell product derived from adult bone marrow. It is designed to promote tissue repair and healing, reduce inflammation, and modulate immune responses. The therapeutic potential of MultiStem has been demonstrated in preclinical and clinical studies across multiple therapeutic areas, including ischemic stroke, acute respiratory distress syndrome (ARDS), trauma injuries, inflammatory bowel disease, and graft-versus-host disease (GVHD).
A key aspect of Athersys' strategy is forming strategic collaborations and partnerships with leading pharmaceutical and biotechnology companies. These collaborations allow them to leverage their platform technologies and expertise while accessing additional resources and capabilities to accelerate the development and commercialization of their products.
In terms of clinical development, Athersys has a robust pipeline of programs targeting various indications. Their lead program is focused on acute ischemic stroke, which is a significant unmet medical need with limited treatment options. Athersys has completed several clinical trials evaluating the use of MultiStem in ischemic stroke patients, including a Phase 2/3 trial in collaboration with Healios K.K. in Japan. Promising results from these trials have shown the potential of MultiStem to improve patient outcomes and reduce disability.
Aside from stroke, Athersys is also actively exploring the use of MultiStem in other areas such as ARDS, trauma, inflammatory bowel disease, and GVHD. The company is conducting clinical trials in these indications to assess the safety and efficacy of MultiStem in diverse patient populations.
In addition to its stem cell platform, Athersys is also exploring other technologies and product candidates. One example is their Optimized Neural Stem Cells (oNSCs) program, which aims to develop therapies for central nervous system (CNS) disorders such as spinal cord injury and multiple sclerosis.
Athersys has a strong research and development focus, with a team of dedicated scientists and clinicians working to advance their pipeline programs. They also have an experienced management team with a track record of success in the biopharmaceutical industry.
Overall, Athersys Inc. is a leading biotechnology company that is leveraging stem cell technology to develop innovative therapies for a range of medical conditions. With a pipeline of promising candidates and strategic partnerships in place, Athersys is positioned to make a significant impact in the field of regenerative medicine.
Athersys, Inc. is a biotechnology company that primarily focuses on the development of regenerative medicine therapies. The companys key offerings are centered around its proprietary MultiStem® cell therapy platform, which consists of several segments, products, and services designed to treat a range of medical conditions through innovative cell-based approaches. Below are the detailed segments, products, and services Athersys, Inc. offers:
1. MultiStem® Cell Therapy Platform
- Description: MultiStem is an allogeneic stem cell therapy derived from bone marrow. This platform involves the isolation and expansion of stem cells, which can be differentiated into various cell types capable of influencing immune responses and promoting tissue repair and regeneration.
- Applications: MultiStem is being investigated for various indications, including:
- Stroke: Research is focused on the use of MultiStem in treating ischemic stroke patients, aiming to improve recovery and reduce disability.
- Traumatic Brain Injury (TBI): MultiStem has shown potential in preclinical studies for enhancing recovery in TBI patients.
- Acute Respiratory Distress Syndrome (ARDS): The therapy is also being utilized to explore treatment opportunities in patients with ARDS, particularly in the context of severe respiratory illnesses.
- Critical Limb Ischemia: Programs are being initiated to evaluate MultiStem for restoring blood flow and promoting healing in patients with severe peripheral artery disease.
Clinical Development Programs
- Athersys is actively conducting multiple clinical trials to evaluate the safety and efficacy of MultiStem. These programs are essential for regulatory approval and demonstrating the therapeutic potential of MultiStem in various settings:
- Phase II Trials: Focused on evaluating the effectiveness of MultiStem in stroke and TBI indications.
- Phase III Trials: Potentially expanding into larger-scale trials based on positive outcomes from earlier phases, particularly for conditions like ischemic stroke.
Partnerships and Collaborations
- Athersys pursues strategic collaborations with other biotechnology firms, research institutions, and healthcare organizations. These partnerships are critical to expand the reach of MultiStem therapies and enhance the clinical trial process:
- Collaborations with Biopharmaceutical Companies: Joint efforts in research and development to leverage combined expertise.
- Academic Partnerships: Collaborating with academic institutions to further study the mechanisms and applications of MultiStem therapy.
Regulatory and Manufacturing Expertise
- Regulatory Affairs: Athersys has a strong focus on regulatory pathways and compliance, facilitating the movement of their products through the clinical trial phases and towards market approval.
- Manufacturing Capabilities: The organization has established advanced manufacturing techniques to produce MultiStem consistently and at the scale required for clinical and commercial use.
Intellectual Property Portfolio
- Athersys actively performs research and development to build its intellectual property portfolio around its MultiStem technology. This portfolio is key in protecting innovations and maintaining competitive advantages in the regenerative medicine space.
Market Research and Insights
- The company conducts ongoing market research to understand the therapeutic landscape, patient needs, and potential market opportunities. This research supports informed decision-making regarding future product development and market strategies.
Education and Advocacy
- Athersys is engaged in educating healthcare providers, patients, and stakeholders about the role of regenerative medicine and the potential benefits of their therapies. They participate in advocacy efforts to promote acceptance and understanding of stem cell therapies.
Conclusion
Athersys Inc. is focused on leveraging its MultiStem platform to address significant unmet medical needs across various therapeutic areas. By conducting clinical trials, engaging in strategic partnerships, and maintaining a robust regulatory and manufacturing framework, Athersys aims to position itself as a leader in the field of regenerative medicine. The company is dedicated to advancing science and improving patient outcomes through innovative therapies.
1. MultiStem® Cell Therapy Platform
- Description: MultiStem is an allogeneic stem cell therapy derived from bone marrow. This platform involves the isolation and expansion of stem cells, which can be differentiated into various cell types capable of influencing immune responses and promoting tissue repair and regeneration.
- Applications: MultiStem is being investigated for various indications, including:
- Stroke: Research is focused on the use of MultiStem in treating ischemic stroke patients, aiming to improve recovery and reduce disability.
- Traumatic Brain Injury (TBI): MultiStem has shown potential in preclinical studies for enhancing recovery in TBI patients.
- Acute Respiratory Distress Syndrome (ARDS): The therapy is also being utilized to explore treatment opportunities in patients with ARDS, particularly in the context of severe respiratory illnesses.
- Critical Limb Ischemia: Programs are being initiated to evaluate MultiStem for restoring blood flow and promoting healing in patients with severe peripheral artery disease.
Clinical Development Programs
- Athersys is actively conducting multiple clinical trials to evaluate the safety and efficacy of MultiStem. These programs are essential for regulatory approval and demonstrating the therapeutic potential of MultiStem in various settings:
- Phase II Trials: Focused on evaluating the effectiveness of MultiStem in stroke and TBI indications.
- Phase III Trials: Potentially expanding into larger-scale trials based on positive outcomes from earlier phases, particularly for conditions like ischemic stroke.
Partnerships and Collaborations
- Athersys pursues strategic collaborations with other biotechnology firms, research institutions, and healthcare organizations. These partnerships are critical to expand the reach of MultiStem therapies and enhance the clinical trial process:
- Collaborations with Biopharmaceutical Companies: Joint efforts in research and development to leverage combined expertise.
- Academic Partnerships: Collaborating with academic institutions to further study the mechanisms and applications of MultiStem therapy.
Regulatory and Manufacturing Expertise
- Regulatory Affairs: Athersys has a strong focus on regulatory pathways and compliance, facilitating the movement of their products through the clinical trial phases and towards market approval.
- Manufacturing Capabilities: The organization has established advanced manufacturing techniques to produce MultiStem consistently and at the scale required for clinical and commercial use.
Intellectual Property Portfolio
- Athersys actively performs research and development to build its intellectual property portfolio around its MultiStem technology. This portfolio is key in protecting innovations and maintaining competitive advantages in the regenerative medicine space.
Market Research and Insights
- The company conducts ongoing market research to understand the therapeutic landscape, patient needs, and potential market opportunities. This research supports informed decision-making regarding future product development and market strategies.
Education and Advocacy
- Athersys is engaged in educating healthcare providers, patients, and stakeholders about the role of regenerative medicine and the potential benefits of their therapies. They participate in advocacy efforts to promote acceptance and understanding of stem cell therapies.
Conclusion
Athersys Inc. is focused on leveraging its MultiStem platform to address significant unmet medical needs across various therapeutic areas. By conducting clinical trials, engaging in strategic partnerships, and maintaining a robust regulatory and manufacturing framework, Athersys aims to position itself as a leader in the field of regenerative medicine. The company is dedicated to advancing science and improving patient outcomes through innovative therapies.